Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program - Levy, G G; Asikanius, E; Kuebler, P; Benchikh El Fegoun, S; Esbjerg, S; Seremetis, S (J Thromb Haemost, 2019)